In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bellerophon Therapeutics Inc.

www.bellerophon.com

Latest From Bellerophon Therapeutics Inc.

Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO

Gossamer took an infrequently used path to go public during a US government shutdown that's kept the SEC from processing new offerings. Also, IPO filings (and withdrawals) and follow-on offerings continued during the shutdown, while VC deals keep up a brisk pace.

Financing Business Strategies

Pipeline Watch: Phase III Progress With Burosumab, Duvelisib And Galcanezumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Phase III Starts With DCC-2618, Tislelizumab And Tabelecleucel

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Deals Shaping The Medical Industry, October 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cardiovascular
  • Respiratory, Pulmonary
  • Alias(es)
  • Bellerophon Therapeutics LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Bellerophon Therapeutics Inc.
  • Senior Management
  • Fabian Tenenbaum, CEO
    Assaf Korner, CFO
    Hunter Gillies, MD, Acting CMO
    Parag Shah, PhD, VP, Bus. Ops.
  • Contact Info
  • Bellerophon Therapeutics Inc.
    Phone: (908) 574-4770
    184 Liberty Corner Rd., Ste. 302
    Warren, NJ 07059
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register